Uveitis

Disease1 paper

Trial sponsors

Sanofi
Company1 trialPhase 258 people
University of California, San Francisco
2 trialsPhase 3296 people
JHSPH Center for Clinical Trials
1 trialPhase 3227 people
Hospital San Carlos, Madrid
1 trialPhase 3192 people
University College London (UCL) Cancer Institute
1 trialPhase 2/350 people
Sun Yat-sen University
2 trialsPhase 240 people
Assistance Publique - Hôpitaux de Paris
1 trialPhase 2112 people
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology
1 trialPhase 250 people

Latest

3

Ageing Research ReviewsReview22 Sep

Immunosenescence in uveitis: From mechanistic insights to therapeutic implications

Drug Discovery TodayReview24 Aug

GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals

GLP-1 receptor agonists

Ophthalmic Surgery, Lasers & Imaging RetinaHumans19 Aug

Prevalence of Potentially Sight-Threatening Pathology Detected by Non-Mydriatic Fundus Photography in a National Diabetic Screening Platform